文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

基于尿苷的PET/NIRF双模态成像用于精准肿瘤诊断与手术

Uridine-Based PET/NIRF Dual-Modality imaging for precision tumor diagnosis and surgery.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-24

本研究合成靶向平衡型核苷转运蛋白1(ENT1)介导尿苷转运的[68Ga]Ga-DOTA-FZUD与ICG-FZUD探针,分别用于PET与NIR-II荧光成像。在胰腺癌等模型中肿瘤摄取显著,肿瘤/肌肉比持续超过3.5,ICG-FZUD可穿透血脑屏障并显示原位胶质母细胞瘤。三例胃癌患者手术标本离体成像证实选择性肿瘤摄取,与组织病理一致。

要点

  • 合成[68Ga]Ga-DOTA-FZUD与ICG-FZUD探针,分别用于PET与NIR-II荧光成像
  • ENT1表达较高的胰腺癌模型肿瘤摄取明显高于ENT1表达较低的模型
  • ICG-FZUD可穿透血脑屏障并显示原位胶质母细胞瘤

核心结论

  • 该ENT1靶向尿苷转运PET/NIRF双模态成像平台可补充传统葡萄糖基成像,并提供实时术中导航。
  • 作者认为其对早期癌症诊断和精准手术具有重要前景和较强的转化潜力。

研究设计与样本

  • 研究合成[68Ga]Ga-DOTA-FZUD和ICG-FZUD探针,分别用于PET和NIR-II荧光成像。
  • 进行小动物PET/CT与NIR-II荧光成像,并分析生物分布。
  • 对三例胃癌患者的手术标本使用ICG-FZUD进行离体NIR-II荧光成像以确认肿瘤靶向性。

主要发现

  • [68Ga]Ga-DOTA-FZUD具有优良的放射化学纯度。
  • 在ENT1表达相对较高的胰腺癌模型(AsPC-1、Panc-1)中,[68Ga]Ga-DOTA-FZUD的肿瘤摄取明显高于ENT1表达较低的模型(MiaPaCa-2、BxPC-3)。
  • 在胃、乳腺和胶质母细胞瘤模型中观察到类似摄取,肿瘤/肌肉比持续超过3.5。
  • ICG-FZUD实现高对比度NIR-II成像并清晰勾勒肿瘤边界,且可穿透血脑屏障显示原位胶质母细胞瘤。
  • 人胃癌组织离体成像证实选择性肿瘤摄取,与组织病理学发现一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metabolic reprogramming allows cancer cells to survive and proliferate under nutrient-deprived conditions. Uridine, a central molecule in pyrimidine metabolism, supports both nucleotide biosynthesis and redox homeostasis. However, high-sensitivity imaging tools for equilibrative nucleoside transporter 1 (ENT1)-mediated uridine transport are lacking, limiting applications in precise diagnosis and intraoperative guidance. This study aimed to develop and validate a novel dual-modality imaging platform targeting ENT1-mediated uridine transport for tumor imaging and surgical navigation. METHODS: We synthesized [68Ga]Ga-DOTA-FZUD and ICG-FZUD probes for PET and NIR-II fluorescence imaging, respectively. Small-animal PET/CT and NIR-II fluorescence imaging were performed, and biodistribution were analyzed. Ex vivo NIR-II fluorescence imaging using ICG-FZUD was performed on surgical specimens from three gastric cancer patients to confirm tumor targeting. RESULTS: [68Ga]Ga-DOTA-FZUD exhibited excellent radiochemical purity. In pancreatic cancer models with relatively higher ENT1 expression (AsPC-1, Panc-1) compared with lower ENT1 expression models (MiaPaCa-2, BxPC-3), [68Ga]Ga-DOTA-FZUD demonstrated markedly greater tumor uptake. Similar uptake was also observed in gastric, breast, and glioblastoma models, with tumor-to-muscle ratios consistently exceeding 3.5. ICG-FZUD enabled high-contrast NIR-II imaging and clearly delineated tumor margins. Notably, ICG-FZUD penetrated the blood-brain barrier and visualized orthotopic glioblastoma. Ex vivo imaging of human gastric cancer tissues confirmed selective tumor uptake, consistent with histopathological findings. CONCLUSION: This ENT1-targeted uridine transport PET/NIRF dual-modality imaging platform complements conventional glucose-based imaging and provides real-time intraoperative navigation. It holds significant promise for early cancer diagnosis and precision surgery with strong translational potential.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bian L, Li P, Chen Y, et al. Uridine-Based PET/NIRF Dual-Modality imaging for precision tumor diagnosis and surgery. Eur J Nucl Med Mol Imaging. 2025. PMID: 40991020. doi:10.1007/s00259-025-07573-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。